Warfarin Adverse Event Reduction for Adults Receiving Genetic Testing at Therapy Initiation.
- Type of Study
- Heart & Vascular - Other Trials
- Short Description
The study is designed to assess if incorporating genotype testing results of CYP2C9 and VKORC1 gene variants into a warfarin dosing protocol can change the number of adverse events related to Warfarin in older subjects (>65) beginning warfarin therapy.
- Principal Investigator
- John Petersen II, MD
- Eligibility Notes
Age 65 or older beginning Warfarin therapy (doses 0-3 taken at the time of enrollment)
- Start Date
- Contact Name
- Jeremy Gillis or Jennifer Nagel
- Alternate Phone
- Alternate Email